These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37762481)

  • 1. The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment.
    Hvas CL; Larsen JB
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment.
    Kanji R; Kubica J; Navarese EP; Gorog DA
    Eur J Clin Invest; 2021 Apr; 51(4):e13471. PubMed ID: 33296082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inherited disorders of the fibrinolytic pathway.
    Jain S; Acharya SS
    Transfus Apher Sci; 2019 Oct; 58(5):572-577. PubMed ID: 31427261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolysis in trauma patients: wide variability demonstrated by the Lysis Timer.
    Roullet S; Weinmann L; Labrouche S; Gisbert-Mora C; Biais M; Revel P; Freyburger G
    Scand J Clin Lab Invest; 2019; 79(1-2):136-142. PubMed ID: 30861350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis Shutdown and Hypofibrinolysis Are Not Synonymous Terms: The Clinical Significance of Differentiating Low Fibrinolytic States.
    Moore HB
    Semin Thromb Hemost; 2023 Jul; 49(5):433-443. PubMed ID: 36318960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macromolecular ensembles of internal and external fibrinolysis: the resources for enhancement of thrombolysis efficacy.
    Maksimenko AV; Tischenko EG
    Curr Med Chem; 2006; 13(14):1617-25. PubMed ID: 16787208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutics targeting the fibrinolytic system.
    Lin H; Xu L; Yu S; Hong W; Huang M; Xu P
    Exp Mol Med; 2020 Mar; 52(3):367-379. PubMed ID: 32152451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in thrombolytic therapy.
    Collen DC; Gold HK
    Thromb Res Suppl; 1990; 10():105-31. PubMed ID: 2180114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolytic Enzymes for Thrombolytic Therapy.
    Kumar SS; Sabu A
    Adv Exp Med Biol; 2019; 1148():345-381. PubMed ID: 31482506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
    Lisman T
    Semin Thromb Hemost; 2017 Mar; 43(2):178-184. PubMed ID: 27472427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications.
    Napolitano F; Montuori N
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated factor XIa as a modulator of plasma fibrin clot properties in coronary artery disease.
    Paszek E; Malinowski KP; Ząbczyk M; Butenas S; Undas A
    Eur J Clin Invest; 2023 Sep; 53(9):e14007. PubMed ID: 37042848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.
    Sun M; Hao Pontius MH; Yang S; Pendekanti T; Raghunathan S; Shavit JA; Sen Gupta A
    J Thromb Haemost; 2023 Apr; 21(4):983-994. PubMed ID: 36696210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Plasmin Generation in Health and Disease.
    Miszta A; Huskens D; Donkervoort D; Roberts MJM; Wolberg AS; de Laat B
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in plasmin inhibitor and fibrinogen predict the improved fibrin clot lysis 6 months after obesity surgery.
    Pedersen NB; Stolberg CR; Mundbjerg LH; Juhl CB; Gram B; Funch-Jensen P; de Maat MPM; Münster AB; Bladbjerg EM
    Clin Obes; 2020 Dec; 10(6):e12397. PubMed ID: 32827201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.